IFI30, Interferon, Gamma-Inducible Protein 30, Drug Target, Biomarker

Target Name: IFI30

NCBI ID: G10437

IFI30

IFI30, Interferon, Gamma-Inducible Protein 30, Drug Target, Biomarker

Introduction

The interferon system is a crucial part of the immune system, which is responsible for fighting off infections and diseases caused by pathogens. Interferon is a protein that plays a vital role in the interferon system, and it is often used as a drug target or biomarker . In this article, we will discuss IFI30, a protein identified as a potential drug target and biomarker for cancer.

The Interferon System

Interferon is a cytoplasmic protein that is involved in the regulation of the immune response. It is produced by the immune cells and is essential for the production of other proteins that are involved in the immune response.

The interferon system consists of two main components: interferon RNA (siRNA) and the interferon protein itself. Interferon RNA is a small RNA molecule that is produced by the immune cells to recruit other immune cells to the site of an infection or cancer. Once recruited , the interferon RNA interacts with the interferon protein, which is a large protein that is produced by the immune cells.

The interferon protein is composed of four superhelical subunits, which form a stable three-dimensional structure through hydrogen bonding interactions. This structure allows the interferon protein to bind to specific sequences on DNA, thereby triggering the intracellular signal transduction pathway of DNA damage and inducing immune cells to produce anti-tumor effects.

GFP-IFN?± fusion protein

GFP-IFN?± fusion protein is a genetically engineered mouse that expresses human IFN?±, and its cells contain hIFN?± gene. The GFP-IFN?± fusion protein has both immunogenicity and reporter gene activity and can be used as a potential biomarker and drug target.

By fusing the GFP gene with the IFN?± gene, a GFP-IFN?± fusion protein can be constructed. This fusion protein possesses both the immunogenicity of IFN?± and the ability to express GFP, allowing scientists to exploit both properties simultaneously to study the function of IFN?±.

The relationship between IFI30 and GFP-IFN?±

IFI30 is a protein with a single polypeptide chain containing an acetylated phenylalanine at its N-terminus. IFI30 has multiple functions in cells, such as regulating the production of immune cells and mediating intracellular signal transduction pathways of DNA damage.

Studies have shown that IFI30 expression is up-regulated in a variety of cancers, such as lung cancer, liver cancer, breast cancer, etc. In addition, the expression level of IFI30 is also positively correlated with tumor invasion and metastasis. Therefore, IFI30 can be used as a potential drug target.

Interaction between IFI30 and GFP-IFN?±

The interaction of IFI30 with GFP-IFN?± can promote the immunogenicity and reporter gene activity of GFP-IFN?±. Specifically, phenylalanine acetylation of IFI30 can enhance the binding of GFP to IFN?±, thereby improving the immunogenicity of GFP-IFN?±. In addition, IFI30 can also regulate the expression level of GFP-IFN?±, thereby increasing the reporting gene activity of GFP-IFN?±.

The findings indicate that IFI30 is a potential drug target that can be used to treat a variety of cancers. At the same time, IFI30 can also be used as a biomarker for GFP-IFN?± to evaluate the therapeutic effect of GFP-IFN?±.

Conclusion

IFI30 is a protein that plays an important role in the immune system. Studies have shown that IFI30 is up-regulated in a variety of cancers and can be used as a potential drug target. At the same time, IFI30 can also be used as a biomarker for GFP-IFN?± to evaluate the therapeutic effect of GFP-IFN?±. Therefore, IFI30 is a potential drug target that can be used to treat various cancers and can be used as a biomarker for GFP-IFN?± to evaluate the therapeutic effect of GFP-IFN?±.

Protein Name: IFI30 Lysosomal Thiol Reductase

Functions: Lysosomal thiol reductase that can reduce protein disulfide bonds. May facilitate the complete unfolding of proteins destined for lysosomal degradation. Plays an important role in antigen processing. Facilitates the generation of MHC class II-restricted epitodes from disulfide bond-containing antigen by the endocytic reduction of disulfide bonds (By similarity). Facilitates also MHC class I-restricted recognition of exogenous antigens containing disulfide bonds by CD8+ T-cells or crosspresentation (By similarity)

The "IFI30 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IFI30 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets